ArticleFrontiers in immunology2016
TNF Neutralization Results in the Delay of Transplantable Tumor Growth and Reduced MDSC Accumulation.
Article in Frontiers in immunology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 38 citations in OpenAlex.
- MDSC checkpoint blockade therapy: a new breakthrough point overcoming immunosuppression in cancer immunotherapy.Cancer gene therapy · 2025Review
- Predictive value of the systemic inflammation grade for overall survival in patients with colorectal cancer after surgery: outperforming NLR and mGPS.Frontiers in oncology · 2025Article
- Tumor necrosis factor regulates leukocyte recruitment but not bacterial persistence during Staphylococcus aureus craniotomy infection.Journal of neuroinflammation · 2024Article
- Mechanisms of myeloid-derived suppressor cell-mediated immunosuppression in colorectal cancer and related therapies.World journal of gastrointestinal oncology · 2024Review
- The Function and Therapeutic Implications of TNF Signaling in MDSCs.Biomolecules · 2022Review
- Pharmacological modulation of myeloid-derived suppressor cells to dampen inflammation.Frontiers in immunology · 2022Review
- Evidence for tmTNF reverse signalingiScience · 2021Article
- Current Perspectives on the Role of TNF in Hematopoiesis Using Mice With Humanization of TNF/LT System.Frontiers in immunology · 2021Article
- Streptococcus bovis Contributes to the Development of Colorectal Cancer via Recruiting CD11b⁺TLR-4⁺ Cells.Medical science monitor : international medical journal of experimental and clinical research · 2020Article
- Targeting EZH2 histone methyltransferase activity alleviates experimental intestinal inflammation.Nature communications · 2019Article
- Screening the Cancer Genome Atlas Database for Genes of Prognostic Value in Acute Myeloid Leukemia.Frontiers in oncology · 2019Article
- Genetic screen in myeloid cells identifies TNF-α autocrine secretion as a factor increasing MDSC suppressive activity via Nos2 up-regulation.Scientific reports · 2018Article
- Eugenol triggers CD11bRSC advances · 2018Article
- Tumor Necrosis Factor α and Regulatory T Cells in Oncoimmunology.Frontiers in immunology · 2018Review
- TNF Receptor 2 Makes Tumor Necrosis Factor a Friend of Tumors.Frontiers in immunology · 2018Review
- Translational Potential of Therapeutics Targeting Regulatory Myeloid Cells in Tuberculosis.Frontiers in cellular and infection microbiology · 2018Review
- PRKCI promotes immune suppression in ovarian cancer.Genes & development · 2017Article
- The Role of Myeloid-Derived Suppressor Cells in Viral Infection.Viral immunology · 2017Review
- VHH-Based Bispecific Antibodies Targeting Cytokine Production.Frontiers in immunology · 2017Article
- Transmembrane Tumor Necrosis Factor Controls Myeloid-Derived Suppressor Cell ActivityFrontiers in immunology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myeloid-derived suppressor cells (MDSCs) represent a heterogeneous population of immature myeloid cells (IMCs) that, under normal conditions, may differentiate into mature macrophages, granulocytes, and dendritic cells. However, under pathological conditions associated with inflammation, cancer, or infection, such differentiation is inhibited leading to IMC expansion. Under the influence of inflammatory cytokines, these cells become MDSCs, acquire immunosuppressive phenotype, and accumulate in the affected tissue, as well as in the periphery. Immune suppressive activity of MDSCs is partly due to upregulation of arginase 1, inducible nitric oxide synthase, and anti-inflammatory cytokines, such as IL-10 and TGF-β. These suppressive factors can enhance tumor growth by repressing T-cell-mediated anti-tumor responses. TNF is a critical factor for the induction, expansion, and suppressive activity of MDSCs. In this study, we evaluated the effects of systemic TNF ablation on tumor-induced expansion of MDSCs in vivo using TNF humanized (hTNF KI) mice. Both etanercept and infliximab treatments resulted in a delayed growth of MCA 205 fibrosarcoma in hTNF KI mice, significantly reduced tumor volume, and also resulted in less accumulated MDSCs in the blood 3 weeks after tumor cell inoculation. Thus, our study uncovers anti-tumor effects of systemic TNF ablation in vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.